8-K: VBI Vaccines Extends Forbearance Agreement with K2 HealthVentures Amidst Revenue Covenant Breach
Current Report
VBI Vaccines has extended its forbearance agreement with K2 HealthVentures to February 20, 2024, due to a failure to meet minimum net revenue covenants.
Summary
- VBI Vaccines and its subsidiary, VBI Cda, have extended their forbearance agreement with K2 HealthVentures to February 20, 2024.
- This extension is due to the company's failure to meet the minimum net revenue covenant for the period ending September 30, 2023, as defined in their Loan Agreement.
- The initial forbearance agreement was entered into on November 13, 2023, and has been extended multiple times.
- There is no guarantee that VBI Vaccines will meet the conditions of the forbearance agreement, which could lead to its termination.
- K2 HealthVentures has not waived VBI's obligation to meet the loan covenants and could declare an event of default after the forbearance period.
- If an event of default occurs, K2 HealthVentures could demand immediate repayment of all obligations, stop further credit extensions, and increase the interest rate by 5.00% per annum.
Sentiment
Score: 3
Explanation: The document highlights significant financial challenges and the risk of default, leading to a negative sentiment.
Negatives
- VBI Vaccines has failed to meet the minimum net revenue covenant, triggering the need for a forbearance agreement.
- There is no assurance that VBI Vaccines will meet the conditions of the forbearance agreement.
- K2 HealthVentures could declare an event of default after the forbearance period.
- An event of default could lead to immediate repayment of all obligations and a 5.00% per annum increase in the interest rate.
Risks
- The company may not meet the conditions of the forbearance agreement, leading to its termination.
- K2 HealthVentures could declare an event of default, which would have significant financial implications for VBI Vaccines.
- The company may not be able to secure another forbearance agreement if an event of default is declared.
- The potential for a 5.00% per annum increase in the interest rate would further strain the company's finances.
Future Outlook
There is no assurance that the Company will be able to meet the conditions set forth in the Forbearance Agreement, which will result in a termination of the Forbearance Period. In addition, the Forbearance Agreement is not a waiver by K2HV of the Company's obligation to meet the covenants pursuant to the Loan Agreement. Accordingly, K2HV may declare an Event of Default after the end of the Forbearance Period.
Management Comments
- Jeffrey R. Baxter, President and Chief Executive Officer, signed the report on behalf of VBI Vaccines Inc.
Industry Context
The biotechnology industry is capital intensive and often relies on debt financing. Failure to meet revenue targets can lead to financial difficulties and renegotiations with lenders, as seen in this case with VBI Vaccines.
Comparison to Industry Standards
- Many biotech companies, especially those in the development stage, face challenges in meeting revenue targets and may require debt financing.
- Forbearance agreements are not uncommon in the industry when companies struggle to meet loan covenants.
- Companies like Novavax and Ocugen have also faced financial challenges and debt restructuring, highlighting the risks associated with biotech financing.
- The 5.00% per annum interest rate increase upon default is a standard penalty in loan agreements.
Stakeholder Impact
- Shareholders face increased risk due to the company's financial difficulties and potential default.
- Employees may be concerned about the company's financial stability.
- Creditors face the risk of non-payment if an event of default occurs.
Next Steps
- VBI Vaccines needs to meet the conditions of the forbearance agreement by February 20, 2024.
- The company may need to negotiate further with K2 HealthVentures to avoid an event of default.
- VBI Vaccines will need to improve its revenue performance to meet its financial obligations.
Key Dates
| Date | Description |
|---|---|
| 2020-05-22 | Date of the original Loan and Guaranty Agreement between VBI Vaccines and K2 HealthVentures. |
| 2023-09-30 | End of the measurement period for the minimum Net Revenue covenant that was not met. |
| 2023-11-13 | Date VBI Vaccines entered into the initial forbearance agreement with K2 HealthVentures. |
| 2023-11-28 | First extension of the forbearance period. |
| 2023-12-12 | Second extension of the forbearance period. |
| 2023-12-26 | Third extension of the forbearance period. |
| 2024-01-09 | Fourth extension of the forbearance period. |
| 2024-01-23 | Fifth extension of the forbearance period. |
| 2024-02-06 | Date of the report and the sixth extension of the forbearance period. |
| 2024-02-20 | End date of the current forbearance period. |
Keywords
forbearance agreement, K2 HealthVentures, loan agreement, net revenue, event of default, covenant breach, debt financing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.